A man in his 80s presented to our hospital's emergency department with left hip pain after falling while transferring from a wheelchair on a visit day. He had been taking clopidogrel for >10 years after atherothrombotic stroke and apixaban 2.5 mg twice a day for 2 years since he was diagnosed with deep vein thrombosis. The patient had no coagulation abnormalities when he started apixaban therapy and had never experienced bleeding events. His medical history included cervical spondylosis surgery, right femoral neck fracture, hypertension, and benign prostatic hypertrophy. Other medications included candesartan, amlodipine, enalapril, tamsulosin, and tadalafil. He denied any overdose of prescribed medications. The patient had no family history of bleeding disorders. He was a nonsmoker and did not drink alcohol.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Medicine
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- [Notes on laboratory coagulation testing for acquired hemophilia A (in Japanese)].Rinsho Byori. 2009; 57: 999-1003
- Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians.J Thromb Haemost. 2018; 16: 209-219https://doi.org/10.1111/jth.13912
- Acquired haemophilia: an often overlooked cause of bleeding - experience from a Hungarian tertiary care centre.Blood Coagul Fibrinolysis. 2012; 23: 584-589https://doi.org/10.1097/MBC.0b013e3283551102
- Acquired hemophilia with inhibitors presenting as an emergency: misinterpretation of clotting results during direct oral anticoagulation.Dtsch Arztebl Int. 2014; 111: 345-348https://doi.org/10.3238/arztebl.2014.0345
- Acquired hemophilia A in an elderly patient on apixaban therapy.Isr Med Assoc J. 2021; 23: 130-131
- "Accessory after the factors": A rare case of an acquired factor VIII inhibitor in a 75-year-old man on rivaroxaban.Cureus. 2021; 13: e18597https://doi.org/10.7759/cureus.18597
- Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation.J Arrhythm. 2016; 32: 42-50https://doi.org/10.1016/j.joa.2015.08.001
- A study on indices of apixaban anticoagulation: a single-center prospective study.J Pharmacol Sci. 2018; 137: 105-109https://doi.org/10.1016/j.jphs.2018.05.001
- Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.Thromb Res. 2015; 136: 148-153https://doi.org/10.1016/j.thromres.2015.04.030
Published online: February 23, 2023
Accepted: January 23, 2023
Received: January 6, 2023Thomas J. Marrie, MD, Section Editor
Publication stageIn Press Journal Pre-Proof
Conflicts of Interest: None.
Authorship: All authors had access to the data and a role in writing this manuscript.
© 2023 Elsevier Inc. All rights reserved.